Infectious Disease Clinics of North America volume 20, issue 1, P81-98 2006 DOI: 10.1016/j.idc.2006.01.001 View full text
|
|
Share
Jeffrey S. Glenn

Abstract: With the advent of second-generation agents that for the first time specifically target individual HCV proteins, HCV-specific therapy has arrived. The study of HCV molecular virology has helped make this possible and is helping us to identify additional new antiviral targets that will be targeted by third-generation drugs. Key to these efforts is the development of high-efficiency HCV replicons. The future effective pharmacologic control of HCV will likely consist of a cocktail of simultaneously administered v…

expand abstract